Comparative cost‐effectiveness of antiviral therapies in patients with chronic hepatitis B: A systematic review of economic evidence

Abstract

Background and Aim: Economic efficiency of the alternative antiviral therapies for chronic hepatitis B has not been systematically investigated and their quality remains unknown. The aim of the present study was to systematically overview economic evidence of antiviral therapies for chronic hepatitis B. Methods: We searched six databases and eight major journals supplemented with screening references of eligible studies. Full economic evaluations comparing alternative antiviral therapies in patients with chronic hepatitis B virus infection were included. Two investigators assessed the study quality and transferability, independently. Data were analyzed qualitatively with adjustment when appropriate. Results: Fourteen studies (six modeling vs eight trials and database analyses) were included. Quality was high in five studies, moderate in one US and five Chinese studies, and low in three Chinese studies. The major problems of quality are costing methods and analysis and the presentation of results. In Australia and Poland, lamivudine-preferred strategies dominated interferon (IFN)-a and its related strategy from the health-care sector

Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation

“…A systematic review of cost-effectiveness of antiviral therapies (Sun and colleagues 48 ) described studies published from 2000 to 2007, including three studies described here (Kanwal and colleagues 38 , Buti and colleagues 47 and Sullivan and colleagues 45 ) and some of the studies identified in our previous review. 12 Sun and colleagues 48 also reviewed other cost studies based on randomised, non-randomised and retrospective cohort data that did not meet the inclusion criteria of the present or previous reviews and were generally assessed by Sun and colleagues 48 as being of moderate or poor quality.…”

“…Four fully published economic evaluations met the inclusion criteria and were included. [44][45][46][47] In addition, one systematic review of economic evidence of cost-effectiveness of antiviral therapies in CHB patients (Sun and colleagues 48 ) was included.…”

Custo-efetividade dos análogos de nucleosídeos/nucleotídeos para hepatite crônica B

“…However, they show methodological differences (the drugs being compared, the timeframe, perspective, modelling) and heterogeneity of the simulated population. 25 Costa et al undertook a study with a ten-year-timeframe comparing entecavir with lamivudine in HBeAg positive and negative patients. 7 Those who developed resistance to lamivudine had adefovir added to their treatment.…”

Reviews on the Epidemiology, Quality of Life, and Management of Chronic Hepatitis B (CHB)

“…It provides a common unit to allow comparisons between different disease groups or intervention programmes (Weinstein, Torrance, & McGuire, 2009). This method is particularly useful in the analysis of preventive health programmes, such as anti-viral treatment in CHB patients (Kanwal et al, 2005;Sullivan et al, 2007;Sun et al, 2007;Yuan et al, 2008).…”

“…Cost-effectiveness analysis (CEA) is an area of increasing interest among researchers, physicians and policy makers (Sun et al, 2007). CEA is a method of summarizing the health benefits and resources used by health programmes, therefore policy makers can select among them (Russell, Gold, Siegel, Daniels, & Weinstein, 1996;Weinstein, 1990;Weinstein, Siegel, Gold, Kamlet, & Russell, 1996).…”